Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -1.27% 7.775 129,801 09:23:03
Bid Price Offer Price High Price Low Price Open Price
7.30 8.25 7.875 7.775 7.875
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.05 -1.48 -0.54 30
Last Trade Time Trade Type Trade Size Trade Price Currency
11:40:20 O 50,000 7.5153 GBX

Eden Research (EDEN) Latest News

More Eden Research News
Eden Research Investors    Eden Research Takeover Rumours

Eden Research (EDEN) Discussions and Chat

Eden Research Forums and Chat

Date Time Title Posts
05/12/202020:00Eden Research8,431
26/8/202008:06Eden Research; novel encapsulation and delivery technologies1,084
07/3/201713:47Eden Research- The Natural Solution172
27/2/201611:20Eden Research- The Natural Solution3
18/5/201201:24Eden Research6

Add a New Thread

Eden Research (EDEN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Eden Research trades in real-time

Eden Research (EDEN) Top Chat Posts

Eden Research Daily Update: Eden Research Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 7.88p.
Eden Research Plc has a 4 week average price of 7.35p and a 12 week average price of 6.58p.
The 1 year high share price is 10.50p while the 1 year low share price is currently 4.65p.
There are currently 380,340,229 shares in issue and the average daily traded volume is 131,554 shares. The market capitalisation of Eden Research Plc is £29,571,452.80.
investingisatrickygame: Super Covid vaccine BioNtech and Pfizer make an announcement the other day that after trials, 90% of those tested with a vaccine improved with no side effects. The markets bought into this future prospect and I think the Dow Jones rose, initially, 1,483. BioNtech is up 30%. It was made clear that they have to get regulatory approval, but they said they were hopeful of the same happening in 4 weeks. The regulators clearly see the importance and apparently, are will to apportion time to hopefully, approve the vaccine so the world's population can be protected and saved where necessary. Eden Research Eden makes announcements (plural) about new product launches and the efficacy of those products that also happen to be pesticide free. The regulators of the agricultural world are apparently moving against pesticide sue and renewal and towards more natural and organic solutions which happens to also be an Eden staple. As a result, Eden's products/solutions are also better for products downstream with human health AND they appear to help yields. The market has priced none of this in, inclusive of Corteva. Eden COULD, if it so chose, come out and make it's own 90% equivalent statement (we have heard anything to the contrary and there is less than a month to go as RNS'd by Eden) to send a signal to the market of what might be. A vaccine might be. Corteva might be. Both require regulatory approval Both have global relevance. Both involve listed companies with responsibilities through the relevant stock exchanges and their equivalent NOMAD's. The world is getting excited about the possibility of a vaccine whilst at the same time still expressing caution and the need for testing. It is however, pricing this into the market (airline stocks rose too) The world or maybe OUR world is not getting excited about Eden, yet we could, I'm sure Eden could send a message to the market about the Corteva situation and I assume, about Insecticides and I assume, about the Sipcam collaboration on Sustaine which was announced over three years ago and has never been commented on since. This vaccine has other competition, so does Eden, but the world is a big place and there is enough room for many to play. Eden could send a signal.
investingisatrickygame: The share price in Eden at this current moment in time is, in my opinion, ridiculous. It is way too low. IF the Corteva deal proceeds as RNS'd and as per the follow up commentary in the Placing RNS, it will be a focal point on value in Eden and how that is assessed. I see three potential situations developing in this circumstance. 1) The Private Investor still doesn't get it or have the confidence to invest which for me means that, the Company will not have communicated value properly as a result of the deal so that value can translate into the share price. Obviously if they do and correct value is invested, all well and good. 2) Institutional investors are now willing to recognise Eden and its future potential and value as a result of the Corteva validation of Eden and as such, they are prepared to go into the market and buy the shares up to the price of X 3)In the event that neither Private Investors OR Institutional Investors BUY Eden shares to a much higher price, Eden would be sat, exposed to industry interest which could develop into a cheap offer in due course. The Corteva deal is an inflexion point for Eden and its Management and we hope that it will be a) successful and b) communication properly such that the RNS, Video and other channels are all explicit about what it means for value in Eden today. Fingers crossed.
investingisatrickygame: Brucie5 From the 28th February Placing RNS Eden stated "The Corteva Agreement The Fundraise will allow the Company to capitalise on opportunities arising from its relationship with Corteva Agriscience. Eden signed an exclusive evaluation agreement with Corteva Agriscience, the world's fourth largest agriculture input company, in January 2020. Significantly for Eden, regulatory change led to the withdrawal of one of Corteva Agriscience's key seed treatment in the EU. Initial trials by Corteva Agriscience have shown strong results using Eden's products and formulation technology. Eden's formulation technology has been shown to be stable, environmentally friendly and complies with emerging EU regulations concerning polymers. Further trials will be undertaken under a one-year evaluation agreement and, subject to the results, Corteva Agriscience and Eden will look to sign a distribution agreement for the EU, Russia, Ukraine and Turkey giving Eden the opportunity to capture a significant share of this market. The Directors estimate that, if successful, there is the opportunity to generate up to c. €40 million of revenue for Eden from European geographies alone (current market) from this product." The 'significantly for Eden' statement combined with the 'c. €40 million of revenue for Eden from European Geographies alone' is somewhat pointing us in a direction in my opinion. So, as I see this, there is more than the value figure stated to come from this anticipated agreement from other territories outside the EU and I hope that revenue at some level can/will be immediate to replace one of Corteva's key seed treatments. This is all opinions and views, but I have posted my maths before to account for my share price valuation and it assumes a level of profit and is not taken from the gross revenue number.
investingisatrickygame: So today there has been over 500,000 in sales. Again, small beer in relation to shares in issue, but in an illiquid stock, damaging to the share price. And a damaged share price erodes confidence and belief and when that happens it triggers more sales, creating a downward spiral. This is why some of the actions suggested above in post 8114 would be so worthwhile for Eden Research Plc, its shareholders and those who might invest. It is also why questions suggested in post 8111 need addressing. If Eden were a brand, it would now have lost its brand value and following. Eden needs to instil faith in its brand. From the messaging we do receive it would appear this is not necessary in its distributor network (Sipcam, Eastman, Corteva maybe) all of whom appear to value Eden's products highly. However, investors, the lifeblood of a Plc don't appear to have faith in Eden. In the absence of some (more than one) blockbuster RNS's that deliver immediate financial impact, Eden has no other recourse to Mcap value save its investor base and potential investor base and it is for this reason that it needs addressing. What isn't working, must be changed where change is possible. For Eden, it is possible? I'd like to know what Cenkos thinks of their client right now and what recommendations, if any, they are making. I'd like to know what Hawthorn thinks of their client right now and what recommendations, if any, they are making. I know I won't get the answer to those, but it would be nice if they were pushing Eden and offering support for change, which ultimately, will make their job of selling and positioning Eden, much easier.
investingisatrickygame: So there has been no trades in Eden for the first two days of this week which suggests to me no urgency to be invested. There is no anticipation around Corteva, no hope, no expectation of Eden landing that deal in the coming months during 2020 (as RNS'd) and if anything, the share price and associated activity doesn't expect Eden to land that deal. Maybe the investment community, those aware and those watching, will wait for a confirmation RNS and chase the price up to reflect that transaction, but this is not a-typical in my experience of how AIM investments work. Surely Eden can deliver some reasonable and realistic communications as to what the Corteva deal means for shareholders if successful and how it would transform the company. When first product sales would occur based on success and what it would mean to the bottom line. This is not hyping the share price, this is informing the market of what a successful deal means for Eden. In the same deliverable they can spell out, for balance, how Eden should be viewed if this deal were not to proceed. The outcome of the above, typically, with the time frame in front of us (less than 4 months) should inject some expectation and enthusiasm into Eden and that wouldn't be unreasonable given the size of the prize. It really is up to Eden to enthuse the market about the Company's prospect in a way that all eyes and ears can understand. And to the contrary, it really is up to Eden NOT to leave investors uneducated in everything Eden so that the Company is so undervalued that it exposes the Company in a number of ways, as well as all of its shareholders. I am still struggling to truly understand Eden's stagnant Market Capitalisation at just £25 million, given all of their IP, product approvals, pending regulatory approvals, Corteval prospects, well advanced insecticide proposition and other stuff of which we are not aware, added to which our corporately successful Chairman has publicly stated during the course of the last 12 months about Eden and where it is going commercially. I'll always advocate that you can't or don't buy what you cannot see and most are not seeing all of this value, largely due to Eden's shortcomings in communicating this message. This view should not be seen as harsh by me as the fully independent barometer that is the share price, is speaking for itself.
investingisatrickygame: Spain RNS hxxps:// "Eden's product, Cedroz, will play a role in solving the issue of large crop losses due to nematode infestation, which globally cost the agriculture industry $80-100 billion each year. Many vegetable species are affected by nematodes and as a result, the use of nematicides on vegetable crops accounts for over 33% of global nematicide sales" MY COMMENT: I do wish Eden would get away from these global numbers which means nothing to Eden and its shareholders. Eden has been quoting these for many years now. Eden's potential market share and associated sales and the global waste values are so disconnected so as to have no meaning at all. I'd have liked Eden to have said and say on all subsequent country approvals that the market for Nematicides in Spain is worth X, the market for Cedroz in Spain is worth Y and jointly, Eden and Eastman over time hope to penetrate Z value/share. This will give shareholders a sense of true direction and true value for the product that Eden has created and found a distributor for. The rest is meaningless. From the Placing RNS hxxps:// Spain €14.4 million On reflection from the Placing RNS of the 28th of February 2020, is it saying that the market for Cedroz in Spain is €14.4 million? If so, what is Eden's share? AND, if it is saying Cedroz in Spain carries a potential market value of €14.4 million why has Eden not made mention of this in this weeks approval RNS and padded it out a bit more? Shareholders can buy into a Company's potential They can get excited about a Company's potential They can be patient with the Company They can trust Management BUT, they have to have concrete information delivered so as to be able to understand Company value, per share value at any given time in order to a) make an investment decision & b) whether to retain an investment proposition or add or subtract from this position. Eden has had long enough to understand this, yet as we expect and hope that RNS newsflow will now build on these approvals, Eden continues to omit vital information to enable investors to make investment decisions and as such, you have a stale share price. Eden simply doesn't knit this information together and deliver in a cohesive manner for a better position for sll shareholders. Share value doesn't have to 'out', its not day. Eden has to show value, explain value, ensure value is understood and gauge their success in this capacity by the upward trajectory of the share price and the share register. Come on Eden, please deliver the next RNS correctly and back it up with a more in-depth piece with Proactive Investors on film so that it can be understood by the many. And whatever we do in positive RNS's and subsequent film, please give shareholders reason to buy this stock. That's totally acceptable in your regulatory framework.
investingisatrickygame: @wilco1000 "I know its a small irrelevant detail but presentation wise Eden are absolutely killing it. Love the website, love the presentations they put out, for a small cap they are certainly in the top leagues." Eden's PPT's are aesthetically pleasing, that is undeniable, but they don't call for investors to buy stock. By that I don't mean a literal statement of the same, but the language and the numbers (market sizes specifically attainable for Eden as opposed to global market values) don't give a sense of what is possible, what is achievable, when and why. Eden would appear to have great products, backed by IP and to be in the right place at the right time; even those that moan about Eden here would likely agree. But they're wearing the wrong suit! By that I mean they are presenting themselves wrong for the investment community (non institutional) and because of this they don't appear to be worthy of investors pounds. If I'm wrong about this the share price would be higher in my opinion, but given it has declined and flatlined over the last number of years then I would advocate there must be some validity in what I say. Investors need reasons to buy into Eden. Corteva is a great one, but Eden has not conveyed the potential correctly. If this were an oil stock who was drilling with a huge barrel potential, I'll venture to say that private investors would be in on the hope of finding oil. Eden is not getting the same gravitas with the like investor base. In my opinion, Eden needs to 1) Present itself differently 2) Understand its audience, what they are looking for and what they need to hear 3) Reach out to that understanding and match their communication to reach this audience 4) Be more buoyant about the prospects within the realms of what they know today 5) Sell their potential prospects for the next year, 2 and 3 6) Explain Eden properly and make sure the listening, reading and watching audience understands Eden properly Again, in my opinion, if Eden did this properly, we would not be sat at 7p, we would be many multiples higher and the benefit of that would be happier shareholders (inclusive of the directors), a fairer representation of Company value, a more stable share price and less pent up demand to sell the stock which is surely coming when Eden's share price rises. Happy shareholders who understand the Company and its value will not sell prematurely. Unhappy shareholders who don't understand the Company and can't see the value will sell at the earliest opportunity to relieve their frustration and to be grateful for their money back. I'm pretty sure this will happen around the 15-20p mark, should Eden get there. What I think Eden needs to do is to anticipate this and ensure they have a band aid or proposition in place at this price point and others to help mitigate any selling and to keep investors, invested. A new suit would help this to be the case.
investingisatrickygame: @erinvale Eden in its previous guises, with previous management, so beit. But let's judge Sean Smith and the last 5 years. Quite a lot has been achieved during that period for a company that is in the market and environment that Eden is. Granted, we now all want to see sales and that requirement is justified. We sit with Mevalone and a widening global reach, a product that is affected by seasonality, but hopefully, global reach and differing climates will smooth this out. Sipcam has the opportunity to provide the Australian market with ample product in readiness for their summer/Autumn period. The onus of sales is on Sipcam, not Eden and Eden should replace Sipcam if the product is really effective, yet Sipcam fails to sell it. That to me is the only argument regarding sales that can be levied at Eden. Cedroz is in the regulatory phase. This year has been unprecedented so some disruption is understandable, but working from home and connections to corporate servers should be standard. So yes, we all hope and expect regulatory approvals for Cedroz to speed through now. Maybe Mike Carroll has some assistive role to play with Eastman to aid progress. Corteva and Seeds - We await the outcome at the end of this year as RNS'd which in isolation could establish annual net sales to Eden, as RNS'd, equal to the value that quizie12 wants to push in their post 8035 (£36 million. Eden's communications still doesn't hit the investor community trigger of "I must/should invest" and it will take a bold step by Eden to correct that. Regulatory approvals are pending with no reason to expect rejections. Regulatory approvals will lead to sales. None of the above takes into account unknown/pending/future commercial agreements to deliver future value to Eden and its shareholders. None of this takes into account Eden's commercial "jack in the box" which is Sustaine. Aside of new agreements, Eden and Sipcam has still yet to RNS the outcome of their commercial collaboration on the same and I think a holding statement is long overdue and one which Eden should acknowledge and therefore comment on.
supersonico: Before back to schoolers get to excited it Seems a good time to remind folk of the incongruence at the heart Eden/TT/ Dow/Bayer public headlice strategy. supersonico - 02 Sep 2019 - 20:02:25 - 6842 of 7964 Eden Research - EDEN Peak Incongruence. Will the Real TT come forward. Good to have the TT web page up again so we can see all the products they have developed over the past nine years but will not be commercialising according to a Eden commissioned report from Cenkos.. but then if you go by Eden RNS statements they may well be ..It's hard to know who in the coming short order to believe. ………………. I Just had to post these 2015 and 2019 chalk and cheese / night and Day / left and right / up and down statements side by side again just so those who did not appreciate the dramatic contrast in Sean Smith 2015 RNS and Sean Smith 2019 commissioned words the first time have the opportunity to have another read. The contrast is remarkable and the headlice epidemic has grown worse since 2015. 2015 TerpeneTech Licence Agreement and Investment Eden's Chief Executive, Sean Smith, commented: "This Agreement is significant to Eden in terms of both the licence fee and the market opportunity. We believe that the combination of Eden's patented GO-E™ encapsulation system with efficacious, low-risk ingredients will provide the differentiator and sustainable competitive advantage required to be successful in this attractive market. "Products that exhibit immediate and sustained efficacy against lice and their eggs, safety, and ease of use are well-positioned to secure market leadership in a relatively short time frame. The incumbent treatments not only fall short with respect to these qualities, but they also suffer when highly-adaptable lice develop resistance to many of the most effective synthetic actives. We believe TerpeneTech's products will fit a major unmet market need. "Eden has worked well with TerpeneTech over the years and is pleased with the contribution that it has made. At this stage it makes sense for Eden to take a larger share in the future value that is being built by TerpeneTech in addition to the royalties that are due to Eden under the existing and new licence agreements. hTTp:// Cenkos 2019 @'Killing it' 'We expect TerpeneTech to launch its headlice treatment in the UK in time for the return to school season in September 2019. At this time, we do not include royalty forecasts for Eden Research, given the size of the UK market means any income is likely to be relatively small. However, if the product is successfully rolled out in larger markets, eg across Europe and into the US, the royalty potential of the product could become more significant.
investingisatrickygame: SHARE PRICE It is hugely disappointing post institutional support and both the Corteva announcement spelling out financials to Eden and the new appointee's for the lab signalling Eden's intentions, that the share price continues to swim in mud. Why is there a continues acceptance or/and apathy towards the share price. Shareholders get despondent and either sell or will sell into any subsequent rise to rid themselves of the emotional burden of their investment. They will look elsewhere and likely fair better elsewhere based on Eden's historical share price performance. There is still a gap in my opinion between the investment community understanding the value in Eden and the value that the investment community ascribes to Eden today. The two don't meet. The question continues to be why and what are Eden and their advisers going to do to rectify the difference?
Eden Research share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Eden Resea..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201206 02:02:22